ArticleInternational journal of molecular sciences2022

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma.

Myra Langendonk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.